open access

Ahead of print
Original paper
Submitted: 2021-03-31
Accepted: 2021-06-30
Published online: 2021-08-06
Get Citation

Non-linear associations of body mass index with impaired fasting glucose, β-cell dysfunction, and insulin resistance in nondiabetic Chinese individuals: a cross-sectional study

Min Chen, Ruihua Yang, Ying Wang, Yumei Jia, Jia Liu, Guang Wang
DOI: 10.5603/EP.a2021.0073
·
Pubmed: 34378785

open access

Ahead of print
Original Paper
Submitted: 2021-03-31
Accepted: 2021-06-30
Published online: 2021-08-06

Abstract

Introduction: Identifying and managing patients with prediabetes is important. The study aims to investigate the association of body mass index (BMI) with impaired fasting glucose (IFG), β-cell dysfunction, and insulin resistance in nondiabetic Chinese individuals. Methods: This was a cross-sectional study of consecutive nondiabetic individuals enrolled between January 2014 and January 2015, divided into the NFG (normal fasting glucose, fasting blood glucose [FBG] <5.6 mmol/L) and IFG (n=450; FBG ≥5.6 mmol/L) groups. Restricted cubic splines and piecewise-regression were used to model the association of IFG, impaired β-cell function, and insulin resistance with BMI. Stratified analyses were performed across sex and age. Results: A total of 900 NFG and 450 IFG individuals were enrolled, with a median age of 41 (30-49) years and 1076 males (79.7%). After adjusting for age and sex, the restricted cubic splines showed that the risk of IFG was increasing rapidly until around 27.96 kg/m2 of BMI and then started to flat afterward (P for non-linearity=0.010), which was similar in males and ≤45 years individuals (P for non-linearity<0.001 and =0.007, respectively). The risk of insulin resistance increased and β-cell dysfunction decreased as the BMI increased in all participants (both P for non-linearity>0.05), consistent with the results in males, females, and ≤45 and >45 years individuals. Conclusions: The risk of IFG is not rising linearly as the BMI increases, and higher BMI seems to decelerate the rise of the risk.

Abstract

Introduction: Identifying and managing patients with prediabetes is important. The study aims to investigate the association of body mass index (BMI) with impaired fasting glucose (IFG), β-cell dysfunction, and insulin resistance in nondiabetic Chinese individuals. Methods: This was a cross-sectional study of consecutive nondiabetic individuals enrolled between January 2014 and January 2015, divided into the NFG (normal fasting glucose, fasting blood glucose [FBG] <5.6 mmol/L) and IFG (n=450; FBG ≥5.6 mmol/L) groups. Restricted cubic splines and piecewise-regression were used to model the association of IFG, impaired β-cell function, and insulin resistance with BMI. Stratified analyses were performed across sex and age. Results: A total of 900 NFG and 450 IFG individuals were enrolled, with a median age of 41 (30-49) years and 1076 males (79.7%). After adjusting for age and sex, the restricted cubic splines showed that the risk of IFG was increasing rapidly until around 27.96 kg/m2 of BMI and then started to flat afterward (P for non-linearity=0.010), which was similar in males and ≤45 years individuals (P for non-linearity<0.001 and =0.007, respectively). The risk of insulin resistance increased and β-cell dysfunction decreased as the BMI increased in all participants (both P for non-linearity>0.05), consistent with the results in males, females, and ≤45 and >45 years individuals. Conclusions: The risk of IFG is not rising linearly as the BMI increases, and higher BMI seems to decelerate the rise of the risk.

Get Citation
About this article
Title

Non-linear associations of body mass index with impaired fasting glucose, β-cell dysfunction, and insulin resistance in nondiabetic Chinese individuals: a cross-sectional study

Journal

Endokrynologia Polska

Issue

Ahead of print

Article type

Original paper

Published online

2021-08-06

DOI

10.5603/EP.a2021.0073

Pubmed

34378785

Authors

Min Chen
Ruihua Yang
Ying Wang
Yumei Jia
Jia Liu
Guang Wang

References (33)
  1. Zhang DD, Tang X, Jin DY, et al. [Prevalence of diabetes in Chinese adults: a Meta-analysis]. Zhonghua Liu Xing Bing Xue Za Zhi. 2018; 39(6): 852–857.
  2. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017; 317(24): 2515–2523.
  3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 Suppl 1: S81–S90.
  4. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9): 829–841.
  5. Ma RC, Lin Xu, Jia W. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014; 2(12): 980–991.
  6. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev . 2005; 26(2): 19–39.
  7. Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001; 86(9): 4047–4058.
  8. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998; 15(4): 297–303, doi: 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W.
  9. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015; 1: 15019.
  10. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487–1495.
  11. Chen G, Liu C, Yao J, et al. Overweight, obesity, and their associations with insulin resistance and β-cell function among Chinese: a cross-sectional study in China. Metabolism. 2010; 59(12): 1823–1832.
  12. Bi Y, Zhu D, Jing Y, et al. Decreased beta cell function and insulin sensitivity contributed to increasing fasting glucose in Chinese. Acta Diabetol. 2012; 49 Suppl 1: S51–S58.
  13. Cerf ME, Cerf ME, Chapman CS, et al. High-fat programming of hyperglycemia, hyperinsulinemia, insulin resistance, hyperleptinemia, and altered islet architecture in 3-month-old wistar rats. ISRN Endocrinol. 2012; 2012: 627270.
  14. Pang C, Bao Yq, Wang C, et al. Relationship between the level of fasting plasma glucose and beta cell functions in Chinese with or without diabetes. Chin Med J. 2008; 121(21): 2119–2123.
  15. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379(9833): 2279–2290.
  16. Genuth S, Alberti KG, Bennett P, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11): 3160–3167.
  17. Joint committee for guideline revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018; 15(1): 1–29.
  18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7): 539–553, doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
  19. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab. 2007; 293(1): E1–E15.
  20. Liu LL, Lawrence JM, Davis C, et al. SEARCH for Diabetes in Youth Study Group. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes. 2010; 11(1): 4–11.
  21. Calanna S, Scicali R, Di Pino A, et al. Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Acta Diabetol. 2014; 51(4): 567–575.
  22. Shashaj B, Luciano R, Contoli B, et al. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol. 2016; 53(2): 251–260.
  23. Bi Y, Zeng L, Zhu D, et al. Association of β-cell function and insulin sensitivity with fasting and 2-h plasma glucose in a large Chinese population. Diabetes Obes Metab. 2012; 14(2): 174–180.
  24. Mitsui R, Fukushima M, Nishi Y, et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism. 2006; 55(1): 53–58.
  25. Sun M, Huang X, Jiang L, et al. Characterization of β-cell function and insulin resistance in overweight Chinese adolescents with normal glucose tolerance. Exp Ther Med. 2013; 6(2): 547–551.
  26. Aguayo-Mazzucato C. Functional changes in beta cells during ageing and senescence. Diabetologia. 2020; 63(10): 2022–2029.
  27. De Tata V. Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne). 2014; 5: 138.
  28. Tramunt B, Smati S, Grandgeorge N, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020; 63(3): 453–461.
  29. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016; 37(3): 278–316.
  30. Khetan AK, Rajagopalan S. Prediabetes. Can J Cardiol. 2018; 34(5): 615–623.
  31. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773–795.
  32. Cho JH, Kim JW, Shin JA, et al. β-cell mass in people with type 2 diabetes. J Diabetes Investig. 2011; 2(1): 6–17.
  33. Zhang L, Qiao Q, Tuomilehto J, et al. DECODE/DECODA Study Group. Distinct ethnic differences in lipid profiles across glucose categories. J Clin Endocrinol Metab. 2010; 95(4): 1793–1801.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl